(Q46986736)

27 December 2017

title

Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience (English)

1 reference

27 December 2017

author name string

S Mastrobuoni

1

1 reference

27 December 2017

M Ubilla

2

1 reference

27 December 2017

A Cordero

3

1 reference

27 December 2017

J Herreros

4

1 reference

27 December 2017

G Rabago

5

1 reference

27 December 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

27 December 2017

Transplantation Proceedings

published in

1 reference

27 December 2017

volume

39

1 reference

27 December 2017

issue

7

1 reference

27 December 2017

page(s)

2163-2166

1 reference

27 December 2017

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.06.073

Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.06.073

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.06.073

Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.06.073

To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.06.073

Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.06.073

Daclizumab to prevent rejection after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.06.073

Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.06.073

Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.06.073

Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.06.073

Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.06.073

Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.06.073

A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas tran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.06.073

A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.06.073

The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.06.073

10.1016/J.TRANSPROCEED.2007.06.073

7 January 2021

Identifiers

DOI

1 reference

27 December 2017

PubMed ID

17889125

1 reference

27 December 2017